Literature DB >> 1109791

Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.

T C Chou, D J Hutchinson, F A Schmid, F S Philips.   

Abstract

The selectivity of action of 1-beta-D-arabinofuranosylcytosine (ara-C) against leukemic cells was studied in vivo. Dynamic state tissue levels of ara-C and of its mono-, di-, and triphosphate (ara-CTP) were measured in L1210 leukemic cells and in C57BL x DBA/2 F1 host tissues at different times after various doses of the agent. The levels were correlated with inhibition of thymidine incorporation into DNA and with cytocidal effects as measured by loss of isotopically prelabeled DNA. ara-CTP levels, but not those of the mono- and diphosphates of ara-C, were higher in leukemic cells and in host cell renewal systems than in other host tissues. DNA synthesis was equally inhibited by similar levels of ara-CTP in ascitic L1210 cells, in leukemic infiltrates in liver, and in small intestine. However, L1210 cells accumulated higher levels of ara-CTP for longer periods than did small intestine, and correspondingly the inhibition of DNA synthesis was greater and more prolonged in leukemic cells. ara-C caused greater losses of prelabeled DNA in ascites cells and in infiltrated liver than in host small intestine. It appears that the differential net tissue level of ara-CTP and its duration are the determinants of chemotherapeutic efficacy of ara-C against L1210 leukemia. ara-C was the predominant nucleoside present in hydrolysates of ara-CTP fractions. By contrast, 1-beta-D-arabinofuranosyluracil predominated in hydrolysates of monophosphate nucleotide fractions from ascites cells, liver, small intestine, and blood. Monophosphate nucleotide was also present in ascites fluid and plasma.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1109791

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  The lethal actions of antitumor agents in proliferating cell systems in vivo.

Authors:  F S Phillips; S S Sternberg
Journal:  Am J Pathol       Date:  1975-10       Impact factor: 4.307

2.  Arabinose nucleoside triphosphates are no inhibitors for DNA-dependent RNA polymerases.

Authors:  W E Müller
Journal:  Experientia       Date:  1976-12-15

3.  Synthesis and tumour-localizing properties of [18F]-5-fluorocytosine-arabinoside and [18F]-5-fluorocyclocytidine.

Authors:  G W Visser; O Zwaagstra; G C Gorree; P Moonen; J D Herscheid; A Hoekstra
Journal:  Eur J Nucl Med       Date:  1986

4.  Effects of cytosine arabinoside on in vivo and in vitro mouse limb development.

Authors:  J M Manson; M L Dourson; C C Smith
Journal:  In Vitro       Date:  1977-07

Review 5.  Selective uptake and retention of anticancer agents by sensitive cells.

Authors:  D L Hill; J A Montgomery
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 6.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

7.  Computer simulation of the cellular immune response to malignant lymphoid cells: logic of approach, model design and laboratory verification.

Authors:  A T Look; T J Schriber; J F Nawrocki; W H Murphy
Journal:  Immunology       Date:  1981-08       Impact factor: 7.397

Review 8.  Membrane transport and the antineoplastic action of nucleoside analogues.

Authors:  F M Sirotnak; J R Barrueco
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

9.  Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo.

Authors:  T Tokui; N Maeda; C Kuroiwa; K Sasagawa; T Inoue; K Kawai; T Ikeda; T Komai
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

10.  Tetrahydrouridine specifically facilitates deoxycytidine incorporation into herpes simplex virus DNA.

Authors:  T W North; C K Mathews
Journal:  J Virol       Date:  1981-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.